Julio A. Poterico 🧑🏻‍💻🇵🇪

MD. Clinical Geneticist. MSc Precision Cancer Medicine | Clinical Bioinfomatics (on the way) Precision and Personalized Medicine | Research & Innovation

[Diego Forero MD, PhD @daforerog]

Artificial intelligence-assisted statistical analysis and statistical review: evidence (2023-2025) and implications for internal medicine
https://t.co/DlbliUbz5L

[Diego Forero MD, PhD @daforerog]

Main sources of analytical variability

https://t.co/sdwRuipCwK

[Diego Forero MD, PhD @daforerog]

RI2, Research Integrity Risk Index

https://t.co/mGn6hiGGAW

[Razia Aliani @RaziaAliani]

Systematic review asks: What works?
Scoping review asks: What exists?
Many researchers confuse the two!

---------------------------------------
Learn in more detail in this accredited course:
🔗 https://t.co/6FSSgwm0M3
----------------------------------------

Here's when a scoping review makes sense:

— You're exploring an emerging area
— You want to identify what research methods people are using
— You need to clarify how a concept is being defined
— You want to spot where the research gaps are

Stick with systematic reviews when:

— You have a focused question
— You need to inform policy or practice decisions
— You want to compare interventions
— Critical appraisal matters for your question

---
1/6

[Diego Forero MD, PhD @daforerog]

PYRAMA: An open-source tool for advanced meta-analysis of genome wide association studies
https://t.co/irozYNB7FI

[Dr Alexey Kulikov @KulikovUNIATF]

Does extreme age inherently mean poor health?

New researchanalyzed the biological profile of a supercentenarian and found a fascinating paradox: canonical markers of #aging (like telomere attrition) coexisted with powerful protective mechanisms. This suggests #longevity isn't about escaping aging, but about maintaining remarkable resilience against age-associated diseases.

The pillars of this resilience include:

🧬 Protective genetics: advantageous alleles for #cardiovascular/brain health and a notable absence of damaging mutations.

🔬 Efficient #metabolism and low inflammation:  favorable lipidomic profile and low #inflammation markers (like IL-6).

🥛 Rejuvenated gut #microbiome: linked to dietary habits like yogurt intake, potentially supported by probiotics (e.g., Bifidobacterium).

🥑 Favorable lifestyle synergy: echoing lessons from Blue Zones (Okinawa, Sardinia, etc.): plant-based diets, integrated #physicalactivity, and strong social bonds.

This study moves ubeyond the quest to simply "slow aging." It frames exceptional longevity as the coexistence of senescence and sustained functional safeguards - a balance of resilience, plasticity, and preserved molecular integrity.

https://t.co/aMPKdVWtaL

[Hasan Toor @hasantoxr]

🚨BREAKING: Google just dropped another hit!

It's called PaperBanana and it generates publication-ready academic illustrations from just your methodology text.

No Figma. No manual design. No illustration skills needed.

Here's how it works:

A team of AI agents runs behind the scenes
→ One finds good diagram examples
→ One plans the structure
→ One styles the layout
→ One generates the image
→ One critiques and improves it

Here's the wildest part:

Random reference examples work nearly as well as perfectly matched ones. What matters is showing the model what good diagrams look like, not finding the topically perfect reference.

In blind evaluations, humans preferred PaperBanana outputs 75% of the time.

This is the recursion we've been waiting for AI systems that can fully document themselves visually.

Waitlist’s open, Link in the first comment.

[María José Calasanz @23_Pares]

Hallmarks of cancer—Then and now, and beyond: Cell https://t.co/mVYZVfiNnC

[Cancer Cell @Cancer_Cell]

Precision oncology and genetic ancestry: The science behind population-based cancer disparities https://t.co/wfd1giMcTF

[Cancer Cell @Cancer_Cell]

Global alliances in translational cancer research https://t.co/MP6ljz78Pp

[María José Calasanz @23_Pares]

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop - eBioMedicine https://t.co/3wpUQIBZfz

[Paolo Tarantino @PTarantinoMD]

No other class of anticancer drug comes close to the number of cures that can be attributed to chemotherapy.

Yet, our understanding of how it truly works is extremely limited.

This perspective on the topic is a must read.

Including for ADC enthusiasts.

https://t.co/WJ99Er8aV9

[Nature Reviews Genetics @NatureRevGenet]

New online! The genetic basis of human height https://t.co/AmSkI3y5As

[María José Calasanz @23_Pares]

Artificial intelligence-based biomarkers for treatment decisions in oncology: Trends in Cancer https://t.co/bsxqJ65bBx

[Brandon Luu, MD @BrandonLuuMD]

Disrupted sleep and circadian rhythms are deeply intertwined with mental health.

They don’t just reflect mental illness—they can drive it. And psychiatric symptoms further disrupt sleep.

Restoring circadian health could be a powerful treatment 🧵 1/12

[Nature Medicine @NatureMedicine]

The Rare Therapies Launchpad: a pilot program for individualized medicines in the UK. Correspondence from Daniel O’Connor, Julia Vitarello and colleagues
@GenomicsEngland @UniofOxford @BostonChildrens Mila’s Miracle Foundation
https://t.co/rApT4ctgvh

[International Society of Liquid Biopsy @isliquidbiopsy]

🔬 The ESMO Tumor-Agnostic Classifier and Screener (ETAC-S) introduces a framework for evaluating molecularly guided therapies beyond tumor type.

💡 Where does Liquid Biopsy fit in?
✅ Enables non-invasive genomic profiling for tumor-agnostic therapies 🩸

✅ Detects targetable alterations in ctDNA for real-time treatment decisions 🎯

✅ Supports longitudinal monitoring of treatment response & resistance 📊

🌍 Liquid biopsy is shaping the future of molecular screening & tumor-agnostic precision oncology!

🔗 Learn more: https://t.co/R68zpFBzVV

@ChristianRolfo @ElJanLe @DrYukselUrun
@UmbertoMalapel1 @drgandara
@MJOSESERRANO19 @oncodaily

#LiquidBiopsy #PrecisionOncology #TumorAgnostic #ctDNA #ISLB 🚀

[International Society of Liquid Biopsy @isliquidbiopsy]

🚨 ctDNA as a Prognostic Biomarker in Esophagogastric Cancer 🧬🩸

🔍 Key Findings from Lander et al., 2024:
✅ Postoperative ctDNA detection predicts recurrence risk 📊
✅ Patients with ctDNA+ in MRD window had 6.2x higher recurrence risk ⚠️
✅ 100% recurrence rate in ctDNA+ patients during surveillance 🚨
✅ Potential for early intervention to improve outcomes 🎯

💡 ctDNA monitoring can refine risk stratification and guide adjuvant therapy decisions in EGC !

📖 Read more: DOI: 10.1200/PO.24.00288
@ChristianRolfo @ElJanLe @DrYukselUrun @UmbertoMalapel1 @drgandara @MJOSESERRANO19 @JCO_ASCO
#Oncology #ctDNA #LiquidBiopsy #MRD #GastricCancer #ISLB 🚀

[Nutrition Science @NutrioSci]

Anti-Aging strategy

[Toni Choueiri, MD @DrChoueiri]

The most quoted paper in Cancer is now published:

Cancer Statistics, 2025

https://t.co/5k48cloYVc